跳到正文
原文
Endpoints News 生物医药· Lei Lei Wu·· 2026-10-19AI 评分56

Disc Medicine 治疗罕见光过敏药物的 III 期临床试验在所有终点均取得成功

Disc Medicine reports 'sun allergy' drug hits Phase 3 home run

AI 导读

Disc Medicine 治疗使阳光照射产生疼痛的罕见疾病的药物在 III 期研究的所有终点均取得成功。

正文

Disc Med­i­cine’s treat­ment for a rare dis­ease that makes sun ex­po­sure painful suc­ceed­ed on all end­points in a Phase 3 study. The re­sult sets the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

来源:Endpoints News 生物医药 · endpoints.news